OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL and Other Hematologic Malignancies

October 15th 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia and other hematologic malignancies.

Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination

October 14th 2021

Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Dr. Roychowdhury on Future Research Directions With FGFR Inhibitors in Cholangiocarcinoma

October 14th 2021

Sameek Roychowdhury, MD, PhD, discusses future research directions with FGFR inhibitors in patients with cholangiocarcinoma.

Dr. Van Tine on Next Steps With Catequentinib in Soft Tissue Sarcoma

October 14th 2021

Brian A. Van Tine, MD, PhD, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma.

Dr. Siddiqui on the Current State of Treatment in Nonmetastatic CRPC

October 14th 2021

Bilal A. Siddiqui, MD, discusses the current state of treatment in nonmetastatic castration-resistant prostate cancer.

Dr. Erba on the Evolution of Treatment in MCL

October 14th 2021

Harry Paul Erba, MD, PhD, discusses the evolution of treatment in mantle cell lymphoma.

Dr. Danilov on the Rationale to Combine Entospletinib With Obinutuzumab in CLL

October 14th 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Catenacci on Recent Updates in GEJ and ESCC Cancers

October 13th 2021

Daniel Catenacci, MD, discusses recent updates in gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Dr. Castaneda Puglianini on Next Steps With CAR T-Cell Therapy in Multiple Myeloma

October 13th 2021

Omar Castaneda Puglianini, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

Dr. Li on the Limitations of the IMpower010 Trial in Resected Stage IB-IIIA NSCLC

October 13th 2021

Bob T. Li, MD, PhD, MPH, discusses the limitations of the phase 3 IMpower010 trial in resected stage IB to IIIA non–small cell lung cancer.

Dr. Johnson on the Promise of DS-7300 in SCLC and Other Advanced Solid Tumors

October 13th 2021

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

Dr. Spira on the Results of the TROPION-PanTumor01 Trial in NSCLC

October 13th 2021

Alexander I. Spira, MD, PhD, FACP, discusses the results of the phase 1 TROPION-PanTumor01 trial in non–small cell lung cancer.

Dr. Verstovsek on the Benefit of JAK Inhibitor Combos in Myelofibrosis

October 13th 2021

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

Dr. Blue on Treatment Considerations for Relapsed/Refractory Multiple Myeloma

October 13th 2021

Brandon Blue, MD, discusses treatment considerations for patients with relapsed/refractory multiple myeloma.

Dr. Rampal on the Importance of Risk Stratification in Myelofibrosis

October 12th 2021

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.

Dr. Thomas on the Rationale for the Phase 2 DDRiver SCLC 250 Trial in SCLC

October 12th 2021

Anish Thomas, MBBS, MD, medical oncologist, Lasker Clinical Research Scholar, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, discusses the rationale for the phase 2 DDRiver SCLC 250 trial in relapsed, platinum-resistant small cell lung cancer.

Dr. Hamilton on the Utility of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

October 12th 2021

Erika P. Hamilton, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Dr. Brayer on Alternatives to CAR T-Cell Therapy in Multiple Myeloma

October 12th 2021

Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma.

Dr. Tsai on Ongoing Research Efforts in Pancreatic Cancer

October 12th 2021

Susan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer.

Dr. Hansen on the Promise of ALLO-715 in Relapsed/Refractory Multiple Myeloma

October 12th 2021

Doris Hansen, MD, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma. Scroll to 0:07 in the video for Dr. Hansen's topline points on the agent.